Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025;28(4):561-581.
doi: 10.2174/0113862073296206240416060154.

Targeted Drug Nanodelivery and Immunotherapy for Combating Tumor Resistance

Yun Liu  1 , Xinyu Sun  2 , Chen Wei  2 , Shoudong Guo  3 , Chunxiao Song  4 , Jiangyu Zhang  5 , Jingkun Bai  6
Affiliations
Review

Targeted Drug Nanodelivery and Immunotherapy for Combating Tumor Resistance

Yun Liu et al. Comb Chem High Throughput Screen. 2025.

Abstract

Chemotherapy resistance is a common cause of tumor treatment failure. Various molecular responses, such as increased expression of efflux transporter proteins, including Pglycoprotein (P-gp), changes in the tumor microenvironment (TME), the role of platelets, and the effects of cancer stem cells (CSCs), can lead to drug resistance. Through extensive research on the mechanisms of drug resistance, more effective anti-resistance drugs and therapeutic approaches are being developed. This review explores drug resistance mechanisms and summarizes relevant anti-resistance drugs. In addition, due to the therapeutic limitations of the aforementioned treatments, new advances in nanocarrier-based combination immunotherapy to address the challenge of drug resistance have been described. Nanocarriers combined with immunotherapy can not only target tumor sites for targeted drug release but also modulate the autoimmune system and enhance immune efficacy, thereby overcoming tumor drug resistance. This review suggests new strategies for overcoming tumor drug resistance and is expected to inform tumor treatment and prognosis.

Keywords: Multidrug resistance; anti-resistance drugs.; chemotherapy; immunotherapy; nanotherapy; targeted drug delivery.

PubMed Disclaimer

References

    1. Namee N.M.; O’Driscoll L.; Extracellular vesicles and anti-cancer drug resistance. Biochim Biophys Acta Rev Cancer 2018,1870(2),123-136 - DOI - PubMed
    1. Zhang L.; Ye B.; Chen Z.; Chen Z.S.; Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers. Acta Pharm Sin B 2023,13(3),982-997 - DOI - PubMed
    1. Alshahrani M.Y.; Alkhathami A.G.; Almoyad M.A.A.; Ahmad M.Z.; Mohanto S.; Ahmad W.; Wahab S.; Phytochemicals as potential inhibitors of interleukin-8 for anticancer therapy: In silico evaluation and molecular dynamics analysis. J Biomol Struct Dyn 2023,2023,1-12 - DOI - PubMed
    1. Joseph M.M.; Ramya A.N.; Vijayan V.M.; Nair J.B.; Bastian B.T.; Pillai R.K.; Therakathinal S.T.; Maiti K.K.; Targeted theranostic nano vehicle endorsed with self‐destruction and immunostimulatory features to circumvent drug resistance and wipe‐out tumor reinitiating cancer stem cells. Small 2020,16(38),2003309 - DOI - PubMed
    1. Shankaran V.; Ikeda H.; Bruce A.T.; White J.M.; Swanson P.E.; Old L.J.; Schreiber R.D.; IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001,410(6832),1107-1111 - DOI - PubMed

Substances

LinkOut - more resources